Zydus Signs a License Agreement with XOMA to Advance IL-2- Based Immuno-Oncology Therapy
Shots:
- Zydus to advance the new IO therapies through formal clinical studies and receives exclusive rights to develop and commercialize the therapy in India- Brazil- Mexico and other emerging markets
- XOMA retains the rights for all other territories and receives royalties on the sales in the licensed territories. The collaboration will combine Zydus’ IL-2 with XOMA’s anti-IL-2 mAb
- Zydus to develop new IO therapy through human POC while each company will receive pre-defined shares of future proceeds that may arise under the license agreement
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Zydus
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com